Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist

被引:122
作者
Pagliara, A
Testa, B [1 ]
Carrupt, PA
Jolliet, P
Morin, C
Morin, D
Urien, S
Tillement, JP
Rihoux, JP
机构
[1] Univ Lausanne, Inst Chim Therapeut, BEP, CH-1015 Lausanne, Switzerland
[2] Univ Paris 12, Fac Med Creteil, Pharmacol Lab, F-94010 Creteil, France
[3] UCB Pharma, B-1420 Braine Alleud, Belgium
关键词
D O I
10.1021/jm9704311
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ionization and lipophilicity behavior of the antihistamine (H-1-receptor antagonist) cetirizine was investigated, showing the drug to exist almost exclusively as a zwitterion in the pH region 3.5-7.5. In this pH range, its octanol/water lipophilicity is constant and low compared to cationic antihistamines (log D = log P-Z 1.5), whereas its H-bonding capacity is relatively large (Delta log P-Z greater than or equal to 3.1). Conformational, electronic, and lipophilicity potential calculations revealed that zwitterionic cetirizine experiences partial intramolecular charge neutralization in folded conformers of lower polarity. Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects. As such, cetirizine does not differ from "second-generation" antihistamines. In contrast, its very low apparent volume of distribution in humans (0.4 L kg(-1), smaller than that of exchangeable water) implies a low affinity for lean tissues such as the myocardium and is compatible with the absence of cardiotoxicity of the drug. The zwitterionic nature and modest lipophilicity of cetirizine may account for this pharmacokinetic behavior. The suggestion is offered that cetirizine and analogous zwitterions, whose physicochemical, pharmacokinetic, and pharmacodynamic properties differ from those of "first-" and "second-generation" drugs in this class, could be considered as "third-generation" antihistamines.
引用
收藏
页码:853 / 863
页数:11
相关论文
共 56 条
[11]   PH LABILITY IN SERUM DURING EQUILIBRIUM DIALYSIS [J].
BRORS, O ;
JACOBSEN, S .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (01) :85-88
[12]   Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety [J].
Caron, G ;
Gaillard, P ;
Carrupt, PA ;
Testa, B .
HELVETICA CHIMICA ACTA, 1997, 80 (02) :449-462
[13]  
Carrupt PA, 1996, LIPOPHILICITY DRUG A, P195
[14]   PHARMACODYNAMIC AND PHARMACOKINETICS OF BW-825C - A NEW ANTIHISTAMINE [J].
COHEN, AF ;
HAMILTON, MJ ;
LIAO, SHT ;
FINDLAY, JWA ;
PECK, AW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (02) :197-204
[15]  
CRAMER CJ, 1995, REV COMPUTATIONAL CH, V6, P1, DOI DOI 10.1002/9780470125830.CH1
[16]  
Dubruc C., 1996, Allergy (Copenhagen), V51, P153
[17]   PHARMACOKINETIC OPTIMIZATION OF HISTAMINE H-1-RECEPTOR ANTAGONIST THERAPY [J].
ESTELLE, F ;
SIMONS, R ;
SIMONS, KJ .
CLINICAL PHARMACOKINETICS, 1991, 21 (05) :372-393
[18]   MOLECULAR LIPOPHILICITY POTENTIAL, A TOOL IN 3D QSAR - METHOD AND APPLICATIONS [J].
GAILLARD, P ;
CARRUPT, PA ;
TESTA, B ;
BOUDON, A .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1994, 8 (02) :83-96
[19]   THE CONFORMATION-DEPENDENT LIPOPHILICITY OF MORPHINE GLUCURONIDES AS CALCULATED FROM THEIR MOLECULAR LIPOPHILICITY POTENTIAL [J].
GAILLARD, P ;
CARRUPT, PA ;
TESTA, B .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (05) :737-742
[20]   ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY - A RAPID ACCESS TO ATOMIC CHARGES [J].
GASTEIGER, J ;
MARSILI, M .
TETRAHEDRON, 1980, 36 (22) :3219-3228